SK
Therapeutic Areas
CRISPR Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| CASGEVY™ (exagamglogene autotemcel) | Transfusion-Dependent Beta Thalassemia | Approved |
| CTX110™ | Relapsed/Refractory B-cell Malignancies (CD19+) | Phase 1 |
| CTX112™ | Relapsed/Refractory B-cell Malignancies (CD19+) | Phase 1 |
| CTX130™ | Relapsed/Refractory T-cell Malignancies (CD70+) | Phase 1 |
| CTX131™ | Relapsed/Refractory Solid Tumors (CD70+) | Phase 1 |
| VCTX210 | Type 1 Diabetes | Preclinical |
| Undisclosed Program | Cardiovascular Disease | Preclinical |
Leadership Team at CRISPR Therapeutics
JR
James R. Kasinger
General Counsel and Secretary
SK
Stephen Kennedy
Head of Technical Operations
MW
Megan Wherry Menner
Head of Human Resources
NP
Naimish Patel, M.D.
Chief Medical Officer
RP
Raju Prasad, Ph.D.
Chief Financial Officer
EC
Emmanuelle Charpentier, Ph.D.
Scientific Founder